<DOC>
	<DOCNO>NCT01826916</DOCNO>
	<brief_summary>EDEMA2 open-label , Phase 2 dose-ranging study design ass safety efficacy repeat dose DX-88 ( recombinant plasma kallikrein inhibitor ) Patients Hereditary Angioedema .</brief_summary>
	<brief_title>EDEMA2 : Evaluation DX-88 's Effect Mitigating Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>10 year age older Documented diagnosis HAE ( Type I II ) Patient report study site later 4 hour follow patient recognition onset attack Willing able give inform consent Patients serious intercurrent illness serious active infection Patient serum creatinine great 110 % upper limit normal liver transaminases 2 time upper limit normal Receipt investigational drug device , within 30 day prior study treatment Pregnancy breastfeed Diagnosis acquire angioedema ( AAE ) Patients complete Day7 followup procedures previously treat attack</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>